



International  
Federation of  
Pharmaceutical  
Manufacturers &  
Associations

Fédération  
Internationale de  
l'Industrie du  
Médicament

Federación  
Internacional de la  
Industria del  
Medicamento



## News Release

### **Health Partnerships Book: Growing Industry Support for Child & Maternal Health, and Chronic Diseases in Developing Countries**

Geneva, 12 May 2009 – The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) today launches the latest edition of its “Partnerships to Build Healthier Societies in the Developing World” book and online database, which can be accessed at [www.ifpma.org/healthpartnerships](http://www.ifpma.org/healthpartnerships). The 2009 edition features a net increase of 21 active programs, after the removal of the 9 programs which were completed during the course of last year. The disease area with the biggest growth was “Child & Maternal Health”, addressing UN Millennium Development Goals 4 & 5, with 6 more programs, while Chronic Disease programs increased by 4.

IFPMA Acting Director General Michael D. Boyd said: “The IFPMA Partnerships Book helps to communicate the research-based industry’s contribution to improving health in developing countries to external stakeholders, especially here in Geneva. It also reflects the fact that the industry works with many Geneva-based partner organizations to achieve this common goal.”

A significant development in the 2009 edition is the presence for the first time of Indian pharmaceutical companies, supporting capacity building, education and research & development programs intended to benefit Indians. A total of five Indian company programs are listed, by Piramal Healthcare (a direct IFPMA member) and Ranbaxy (a member via IFPMA’s Indian member association, OPPI), in R&D for tuberculosis, malaria and dengue, and with capacity building and education programs in Child & Maternal Health and in Chronic Diseases.

Also new in the 2009 edition, under the heading “Additional Health Initiatives”, are full entries for programs which do not address a single specific disease or disease area, but help to strengthen general health care capacity. These programs now get the same visibility as disease-specific programs and also show up in the results of search queries in the online database. This provides a more representative overview of industry support and helps increase the total number of programs active in certain developing countries. For example, the total number of programs active in Kenya is now 43, compared to 36 last year.

**(ends)**

**About the IFPMA:**

The International Federation of Pharmaceutical Manufacturers & Associations is the global non-profit NGO representing the research-based pharmaceutical, biotech and vaccine sectors. Its members comprise 26 leading international companies and 44 national and regional industry associations covering developed and developing countries. The industry's R&D pipeline contains hundreds of new medicines and vaccines being developed to address global disease threats, including cancer, heart disease, HIV/AIDS and malaria. The IFPMA Clinical Trials Portal ([www.ifpma.org/ClinicalTrials](http://www.ifpma.org/ClinicalTrials)), the IFPMA's Ethical Promotion online resource ([www.ifpma.org/EthicalPromotion](http://www.ifpma.org/EthicalPromotion)) and its Developing World Health Partnerships information ([www.ifpma.org/HealthPartnerships](http://www.ifpma.org/HealthPartnerships)) help make the industry's activities more transparent. The IFPMA strengthens patient safety by improving risk assessment of medicines and combating their counterfeiting. It also provides the secretariat for the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).

**For further information, please contact:**

Guy Willis  
Director of Communications  
E-mail: [g.willis@ifpma.org](mailto:g.willis@ifpma.org)  
Tel: +41 22 338 32 00  
Fax: +41 22 338 32 99  
Web: [www.ifpma.org](http://www.ifpma.org)